BRCA1 and neoplasm: Of the 331 tumor samples analyzed from the non-gBRCAm cohort, 283 (85.5%, 283/331) were BRCA wild type (BRCAwt) with no detectable deleterious or suspected deleterious mutation in BRCA1/2, and 48 (14.5%, 48/331) carried deleterious or suspected deleterious somatic BRCA1/2 mutations (sBRCAm; Supplementary Fig. S2A).